Search

Your search keyword '"Mangala LS"' showing total 126 results

Search Constraints

Start Over You searched for: Author "Mangala LS" Remove constraint Author: "Mangala LS"
126 results on '"Mangala LS"'

Search Results

2. EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer.

3. Enhancing oral delivery of plant-derived vesicles for colitis.

4. Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L.

5. Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer.

6. Broad-acting therapeutic effects of miR-29b-chitosan on hypertension and diabetic complications.

8. Molecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma.

9. Author Correction: Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation.

10. Targeting CCR2 + macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer.

12. Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling.

13. MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer.

14. CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance.

19. Inactivating Mutations of the IK Gene Weaken Ku80/Ku70-Mediated DNA Repair and Sensitize Endometrial Cancer to Chemotherapy.

20. Combined VEGFR and MAPK pathway inhibition in angiosarcoma.

21. Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy.

23. ATP11B mediates platinum resistance in ovarian cancer.

24. Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype.

25. The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis.

26. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.

28. Sustained Adrenergic Activation of YAP1 Induces Anoikis Resistance in Cervical Cancer Cells.

29. Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer.

30. Author Correction: Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression.

33. miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer.

34. A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis.

35. Identifying and targeting angiogenesis-related microRNAs in ovarian cancer.

36. Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors.

38. Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis.

39. GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition.

40. PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis.

41. PRKRA /PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer.

42. Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.

43. Bone protection by inhibition of microRNA-182.

44. FABP4 as a key determinant of metastatic potential of ovarian cancer.

45. ATP11B mediates platinum resistance in ovarian cancer.

46. Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction.

48. Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy.

49. ADH1B promotes mesothelial clearance and ovarian cancer infiltration.

50. RNA interference-based therapy and its delivery systems.

Catalog

Books, media, physical & digital resources